Results 101 to 110 of about 8,834,434 (252)
Advances in the delivery of buprenorphine for opioid dependence
Drug Design, Development and Therapy, 2017 Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
doaj
Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?
Substance Abuse Treatment, Prevention, and Policy, 2019 Background The current opioid overdose epidemic affecting communities across North America is increasingly driven by illicitly manufactured fentanyl and its related analogues.
Geoff Bardwell, Evan Wood, Rupinder Brar
doaj +1 more source
Alcohol use in opioid agonist treatment [PDF]
, 2016 Alcohol misuse among individuals receiving agonist treatment for an opioid use disorder is common and is associated with significant morbidity and mortality.
Jan Klimas +5 more
core +1 more source
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold ...
Stefano Damiani +73 more
wiley +1 more source
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Background Suicide risk is elevated after prison release, but population‐level evidence on temporal risk patterns and associated factors remains limited. We aimed to describe characteristics of individuals who die by suicide after release from Norwegian prisons, compare their suicide mortality with the general population, and examine risk ...
Anne Bukten +11 more
wiley +1 more source
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Addiction, EarlyView.Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source
Addiction, EarlyView.Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock +8 more
wiley +1 more source
Varenicline for cannabis use disorder: A randomized controlled trial
Addiction, EarlyView.Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
National opioid pharmacotherapy statistics annual data collection 2012 [PDF]
, 2013 On a snapshot day in 2012, almost 47,000 clients received pharmacotherapy treatment for their opioid dependence at 2,226 dosing points around Australia, this report finds.SummaryAlmost 47,000 Australians received pharmacotherapy treatment for their ...
core
Addiction, EarlyView.Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source